Phathom upgraded at Barclays following pullback, Voquezna optimism

 

• Barclays upgraded Phathom Pharmaceuticals (PHAT) to overweight from equal weight following a huge share decline year to date on growing indications that sales of Voquezna (vonoprazan) will ramp up in Q2.
• The bank raised its price target to $18 from $16 (~67% upside based on March 26 close).
• Phathom shares are down ~36% YTD. However, analyst Jenna Dividner said that the pullback, along with an expected uptick in prescriptions for heartburn drug Voquezna from Q2 through the end of the year, provides an attractive entry point.
• "Trends in March are positive, with the most recent week (3/13) topping peak levels in 4Q25," she wrote. "While 1Q overall is trending flat sequentially, we acknowledge that the latest weekly data points are increasingly positive, and a continuation of these trends could shift stock momentum in a more positive direction."
• Dividner added that the company's targeted commercial approach to gastrointestinal providers rather than a GI and primary care focus "may prove to be a tailwind to drive increased adoption."  

https://www.msn.com/en-us/money/topstocks/phathom-upgraded-at-barclays-following-pullback-voquezna-optimism/ar-AA1Zye6A